

Information For the User
Trimetazidine Hydrochloride I.P. 35mg Tablets

Trizapime 35 MR Tablet

Brand Name: Trizapime 35 MR Tablet

Composition:

Each modified release tablet contains
Trimetazidine Hydrochloride IP 35 mg

Therapeutic Indication:

Indicated as an add-on therapy for the management of stable angina pectoris in adults inadequately controlled by or intolerant to first-line antianginal agents such as beta-blockers or calcium channel blockers
Helps improve myocardial glucose utilization and cellular tolerance to ischemia

Mechanism of Action:

Trimetazidine is a metabolic anti-ischemic agent
It acts by selectively inhibiting long-chain 3-ketoacyl-CoA thiolase in the mitochondria thereby promoting glucose oxidation over fatty acid oxidation
This improves myocardial energy efficiency preserves intracellular ATP levels and protects against ischemia-induced cellular dysfunction without affecting heart rate or blood pressure

Dosage & Administration:

Recommended adult dose: one tablet twice daily preferably in the morning and evening with meals
Do not crush or chew the tablet
Use as an adjunct to standard therapy
Dose adjustment may be required in elderly patients or those with renal impairment

Contraindications:

Hypersensitivity to Trimetazidine or any component of the formulation
Parkinson's disease movement disorders or severe renal impairment (creatinine clearance <30 mL/min)

Warnings & Precautions:

Not recommended for use as monotherapy in unstable angina or myocardial infarction
Use with caution in elderly patients and those with moderate renal dysfunction
Discontinue treatment if symptoms such as tremor rigidity or gait disorders appear
Monitor for signs of extrapyramidal symptoms during prolonged use

Side Effects:

Common: dizziness headache abdominal pain dyspepsia
Less common: rash pruritus asthenia
Rare: extrapyramidal symptoms thrombocytopenia liver enzyme elevation

Storage:

Store in a cool dry and dark place below 25°C

Protect from light and moisture
Keep out of reach of children

Packaging:

Trizapime 35 MR Tablet is available in strip or blister packs

Schedule:

Schedule H Prescription Drug – To be sold by retail on the prescription of a registered medical practitioner only

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for